Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Highlighted Prostate Cancer Trials and Studies

As part of Us TOO’s continued commitment to bring news of new interventions and treatments for the benefit of prostate cancer patients, we are pleased to share this news with you about the following opportunities to participate in clinical trials.


Metastatic Castration-Resistant Prostate Cancer

Read about four clinical trials from Merck for metastatic castration-resistant prostate cancer at https://merckoncologyclinicaltrials.com/en-us/patient/prostate.

Hormone refractory/hormone resistant AND Metastatic:


Men with metastatic castration-resistant prostate cancer are invited to consider enrollment in one of two international, Pfizer-sponsored studies of talazoparib:

  • TALAPRO-1: A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT) NCT03148795

  • TALAPRO-2: A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) NCT03395197

    For an overview of these studies in patient-friendly language, visit: talaprotrials.com

Men with metastatic castration-resistant prostate cancer are invited to consider enrollment in the following Janssen-sponsored studies:

  • KRONOS (56021927PCR2032) – “An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination with Apalutamide in Subjects with Metastatic Castration Resistant Prostate Cancer”


    The MAGNITUDE Study is a Phase 3 randomized, placebocontrolled, doubleblind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.

    Learn More


    Janssen Research & Development is seeking men in the US to participate in a clinical trial of an oral investigational medication for prostate cancer. All participants will receive daily investigational medication. To learn more about the Galahad study and find out if you may be eligible, please visit: www.clinicaltrials.gov Study Identifier: NCT02854436
    Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Multiple trials

  • Prostate cancer trials at the NIH Clinical Center in Bethesda, MD [080706]

    The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), conducts more than 150 clinical trials at the NIH Clinical Center in Bethesda, MD. NCI is currently conducting clinical trials for patients with prostate cancer.

    There is no charge for medical care received at the NIH Clinical Center. Study participants will be responsible for travel costs for their initial screening visits. Once participants are enrolled in a trial, NCI will pay for the transportation costs for all subsequent trial-related visits for participants who do not live in the local area. In addition, these participants will receive a small per diem for food and lodging expenses if they are being treated as outpatients.

    For more information on clinical trials conducted at NCI, please visit https://www.cancer.gov/about-cancer/treatment/clinical-trials or call the Clinical Trials Referral Office (formerly Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937). 

    The National Cancer Institute also sponsors clinical studies at cancer centers nationwide. To learn more about these studies, call 1-800-4-CANCER (1-800-422-6237).